董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Allen Barbieri | 男 | Executive Vice-Chairperson of the Board and Corporate Secretary | 67 | 12.79万美元 | 未持股 | 2025-12-12 |
| Zackary Irani | 男 | Chief Executive Officer and Director | 59 | 20.10万美元 | 未持股 | 2025-12-12 |
| Eric Bing Chin | 男 | Independent Director | 41 | 未披露 | 未持股 | 2025-12-12 |
| Gary Huff | 男 | Independent Director | 58 | 未披露 | 未持股 | 2025-12-12 |
| David Moatazedi | 男 | Independent Director | 47 | 7.92万美元 | 未持股 | 2025-12-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Allen Barbieri | 男 | Executive Vice-Chairperson of the Board and Corporate Secretary | 67 | 12.79万美元 | 未持股 | 2025-12-12 |
| Zackary Irani | 男 | Chief Executive Officer and Director | 59 | 20.10万美元 | 未持股 | 2025-12-12 |
| Gary Lu | 男 | Chief Financial Officer | 45 | 31.18万美元 | 未持股 | 2025-12-12 |
董事简历
中英对照 | 中文 | 英文- Allen Barbieri
-
Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
Allen Barbieri served as an Executive Director and as Vice Chairperson and Corporate Secretary of the Company since Augt 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through Augt 2020, Mr. Allen Barbieri also served as an outside independent director of the Company From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrt REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trt, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Allen Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Allen Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachetts Institute of Technology (MIT). - Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
- Allen Barbieri served as an Executive Director and as Vice Chairperson and Corporate Secretary of the Company since Augt 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through Augt 2020, Mr. Allen Barbieri also served as an outside independent director of the Company From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrt REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trt, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Allen Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Allen Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachetts Institute of Technology (MIT).
- Zackary Irani
-
Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
Zackary Irani has served as a Director, Chief Executive Officer of the Company since April 1997. Until June 2024, Mr. Zackary Irani served as the Chairperson of the Board from April 1997. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Biness Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Zackary Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Zackary Irani holds a BS degree and an MBA degree from the University of California, Irvine The Paul Merage School of Biness. - Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
- Zackary Irani has served as a Director, Chief Executive Officer of the Company since April 1997. Until June 2024, Mr. Zackary Irani served as the Chairperson of the Board from April 1997. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Biness Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Zackary Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Zackary Irani holds a BS degree and an MBA degree from the University of California, Irvine The Paul Merage School of Biness.
- Eric Bing Chin
-
Eric Bing Chin自2025年6月起担任公司董事。Chin先生自2023年1月起担任Akido Labs，Inc.的首席财务官，并自2023年12月起担任Rhode Island Primary Care Physicians Corporation的董事会成员、财务主管和秘书。2018年至2022年，Chin先生在Astrana Health担任首席财务官，该公司是一家上市公司，也是标普 SmallCap 600的成员。2011年至2018年，Chin先生曾在大众仓储和亚历山大房地产担任财务领导职务，这两家公司均为上市公司，是标普 500的成员。从2002年到2011年，Chin先生是一家全球性公共会计师事务所EY的执业注册会计师。Chin先生拥有加州大学洛杉矶分校的学士学位。
Eric Bing Chin has served as a Director of the Company since June 2025. Mr. Chin has served as the Chief Financial Officer of Akido Labs, Inc. since January 2023 and as a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation since December 2023. From 2018 to 2022, Mr. Chin served as Chief Financial Officer at Astrana Health, a publicly traded company and member of the S&P SmallCap 600. From 2011 to 2018, Mr. Chin served in finance leadership positions within Public Storage and Alexandria Real Estate Equities, both of which are publicly traded and members of the S&P 500. From 2002 to 2011, Mr. Chin was a practicing CPA with EY, a global public accounting firm. Mr. Chin holds a BA degree from UCLA. - Eric Bing Chin自2025年6月起担任公司董事。Chin先生自2023年1月起担任Akido Labs，Inc.的首席财务官，并自2023年12月起担任Rhode Island Primary Care Physicians Corporation的董事会成员、财务主管和秘书。2018年至2022年，Chin先生在Astrana Health担任首席财务官，该公司是一家上市公司，也是标普 SmallCap 600的成员。2011年至2018年，Chin先生曾在大众仓储和亚历山大房地产担任财务领导职务，这两家公司均为上市公司，是标普 500的成员。从2002年到2011年，Chin先生是一家全球性公共会计师事务所EY的执业注册会计师。Chin先生拥有加州大学洛杉矶分校的学士学位。
- Eric Bing Chin has served as a Director of the Company since June 2025. Mr. Chin has served as the Chief Financial Officer of Akido Labs, Inc. since January 2023 and as a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation since December 2023. From 2018 to 2022, Mr. Chin served as Chief Financial Officer at Astrana Health, a publicly traded company and member of the S&P SmallCap 600. From 2011 to 2018, Mr. Chin served in finance leadership positions within Public Storage and Alexandria Real Estate Equities, both of which are publicly traded and members of the S&P 500. From 2002 to 2011, Mr. Chin was a practicing CPA with EY, a global public accounting firm. Mr. Chin holds a BA degree from UCLA.
- Gary Huff
-
Gary Huff，医疗保健行业杰出的领导者，在实验室领域拥有超过35年的经验。作为Starboost Health的联合创始人和Take Charge，LLC的创始人兼总裁，他因其为私募股权公司、医院、卫生系统以及独立的临床和解剖病理学实验室提供的战略咨询服务而备受推崇。值得注意的是，他因指导他们完成实验室外联资产出售流程而深受医院和卫生系统高管的尊敬。Huff曾担任过多个高管职务，包括LabCorp Diagnostics的首席执行官、Baylor Genetics的首席执行官以及Solstas Lab Partners的首席运营官。
Gary Huff,a distinguished leader in the healthcare industry, has over 35 years of experience in the laboratory field. As the co-founder of Starboost Health and the founder and president of Take Charge, LLC, he is highly regarded for his strategic advisory services, which he provides to private equity firms, hospitals, health systems, and independent clinical and anatomic pathology laboratories. Notably, he is well respected by hospital and health system executives for guiding them through the laboratory outreach asset sales process.Mr. Huff has held several executive roles, including Chief Executive Officer of LabCorp Diagnostics, Chief Executive Officer of Baylor Genetics, and Chief Operating Officer of Solstas Lab Partners. - Gary Huff，医疗保健行业杰出的领导者，在实验室领域拥有超过35年的经验。作为Starboost Health的联合创始人和Take Charge，LLC的创始人兼总裁，他因其为私募股权公司、医院、卫生系统以及独立的临床和解剖病理学实验室提供的战略咨询服务而备受推崇。值得注意的是，他因指导他们完成实验室外联资产出售流程而深受医院和卫生系统高管的尊敬。Huff曾担任过多个高管职务，包括LabCorp Diagnostics的首席执行官、Baylor Genetics的首席执行官以及Solstas Lab Partners的首席运营官。
- Gary Huff,a distinguished leader in the healthcare industry, has over 35 years of experience in the laboratory field. As the co-founder of Starboost Health and the founder and president of Take Charge, LLC, he is highly regarded for his strategic advisory services, which he provides to private equity firms, hospitals, health systems, and independent clinical and anatomic pathology laboratories. Notably, he is well respected by hospital and health system executives for guiding them through the laboratory outreach asset sales process.Mr. Huff has held several executive roles, including Chief Executive Officer of LabCorp Diagnostics, Chief Executive Officer of Baylor Genetics, and Chief Operating Officer of Solstas Lab Partners.
- David Moatazedi
-
David Moatazedi，自2018年5月起担任Evolus, Inc.总裁、首席执行官和Evolus董事会成员。在此之前，莫阿塔泽迪于2016年3月至2018年5月担任艾尔建公司的高级副总裁，以及美国医疗美学部门的部门主管，该部门包括面部美学、整形外科、再生医学、身体轮廓和皮肤护理产品。从2017年3月至2020年6月，Moatazedi先生担任Obalon Therapeutics, Inc.的董事会成员，该公司是一家公共医疗设备公司，专注于开发和商业化医疗设备，通过促进减肥来治疗肥胖和超重的人。Moatazedi先生自2005年3月起在艾尔建担任各种领导职务，包括2014年8月至2016年3月担任美国面部美学部门销售和营销副总裁，2013年2月至2014年8月担任美国整形外科部门销售和市场副总裁。在Allergan之前，Moatazedi先生是诺华制药皮肤科部门的地区经理。莫阿塔泽迪拥有佩珀代因大学的工商管理硕士学位和加州州立大学长滩分校的学士学位。我们认为，Moatazedi先生丰富的领导经验、他作为Evolus总裁兼首席执行官的职位、对Evolus公司的了解和行业知识使他有资格担任董事会成员。其他上市公司董事职务：Moatazedi先生自2022年12月起担任Biomerica公司董事会成员。Moatazedi先生曾于2017年3月至2020年6月担任Obalon Therapeutics公司董事会成员。
David Moatazedi has served as a Director of the Company since September 2020. Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of board of directors of Evol, Inc. ("Evol") (NASDAQ: EOLS), since May 2018. Evol is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, Mr. David Moatazedi served as Senior Vice President at Allergan Inc. ("Allergan"), and head of the U.S. Medical Aesthetics division. Mr. David Moatazedi also worked in vario other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics, and the U.S. Plastic Surgery Divisions. Before Allergan, from 2000 to 2005 Mr. David Moatazedi was a district manager for Novartis Pharmaceuticals, a multinational pharmaceuticals company. Mr. David Moatazedi holds, an MBA from Pepperdine University and a BA degree from California State University, Long Beach. - David Moatazedi，自2018年5月起担任Evolus, Inc.总裁、首席执行官和Evolus董事会成员。在此之前，莫阿塔泽迪于2016年3月至2018年5月担任艾尔建公司的高级副总裁，以及美国医疗美学部门的部门主管，该部门包括面部美学、整形外科、再生医学、身体轮廓和皮肤护理产品。从2017年3月至2020年6月，Moatazedi先生担任Obalon Therapeutics, Inc.的董事会成员，该公司是一家公共医疗设备公司，专注于开发和商业化医疗设备，通过促进减肥来治疗肥胖和超重的人。Moatazedi先生自2005年3月起在艾尔建担任各种领导职务，包括2014年8月至2016年3月担任美国面部美学部门销售和营销副总裁，2013年2月至2014年8月担任美国整形外科部门销售和市场副总裁。在Allergan之前，Moatazedi先生是诺华制药皮肤科部门的地区经理。莫阿塔泽迪拥有佩珀代因大学的工商管理硕士学位和加州州立大学长滩分校的学士学位。我们认为，Moatazedi先生丰富的领导经验、他作为Evolus总裁兼首席执行官的职位、对Evolus公司的了解和行业知识使他有资格担任董事会成员。其他上市公司董事职务：Moatazedi先生自2022年12月起担任Biomerica公司董事会成员。Moatazedi先生曾于2017年3月至2020年6月担任Obalon Therapeutics公司董事会成员。
- David Moatazedi has served as a Director of the Company since September 2020. Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of board of directors of Evol, Inc. ("Evol") (NASDAQ: EOLS), since May 2018. Evol is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, Mr. David Moatazedi served as Senior Vice President at Allergan Inc. ("Allergan"), and head of the U.S. Medical Aesthetics division. Mr. David Moatazedi also worked in vario other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics, and the U.S. Plastic Surgery Divisions. Before Allergan, from 2000 to 2005 Mr. David Moatazedi was a district manager for Novartis Pharmaceuticals, a multinational pharmaceuticals company. Mr. David Moatazedi holds, an MBA from Pepperdine University and a BA degree from California State University, Long Beach.
高管简历
中英对照 | 中文 | 英文- Allen Barbieri
Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
Allen Barbieri served as an Executive Director and as Vice Chairperson and Corporate Secretary of the Company since Augt 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through Augt 2020, Mr. Allen Barbieri also served as an outside independent director of the Company From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrt REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trt, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Allen Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Allen Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachetts Institute of Technology (MIT).- Allen Barbieri，2015年6月任职董事会以来，他一直担任Biomerica, Inc.董事会的成员。他目前担任Biosynthetic Technologies, LLC的董事长兼首席执行官（2009年12月以来）。此前，他曾任职Lancer Orthodontics, Inc.的董事会，并担任Lancer Orthodontics, Inc.的首席执行官（2004年4月至2008年6月）。1999年至2004年4月，他曾处于半退休状态，担任几个私人公司的董事会的董事。他一直担任Biomerica, Inc.的董事（1999年以来）。1998年至1999年，他曾担任BUY.COM（一个大型网络零售商，拥有超过2亿美元资金的风险投资）的总裁兼首席财务官。1994年至1998年，他曾担任Pacific National Bank（商业银行于1998年出售给US Bank）的总裁兼首席执行官。任职Pacific National Bank期间，他曾担任Alta Residential Mortgage Trust（按揭房地产投资信托基金，其最大股东和创始人是Lehman Brothers）的首席执行官。此前，他曾担任Capital Bancorp（商业银行控股公司）的总裁、First Federal Bank的首席财务官，以及Merrill Lynch Capital Markets（位于纽约）投资银行副合伙人。他持有Brigham Young University的工商管理学士学位，以及麻省理工学院的斯隆管理学院（the Massachusetts Institute of Technology, Sloan School of Management）的工商管理硕士学位。
- Allen Barbieri served as an Executive Director and as Vice Chairperson and Corporate Secretary of the Company since Augt 2020. Since January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of Küleon LLC, a small private biotech company engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through Augt 2020, Mr. Allen Barbieri also served as an outside independent director of the Company From March 2015 to April 2022, Mr. Allen Barbieri served as a member of the board of directors of CareTrt REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trt, where he served as Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January 2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Allen Barbieri served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994 to 1999 Mr. Allen Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachetts Institute of Technology (MIT).
- Zackary Irani
Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
Zackary Irani has served as a Director, Chief Executive Officer of the Company since April 1997. Until June 2024, Mr. Zackary Irani served as the Chairperson of the Board from April 1997. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Biness Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Zackary Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Zackary Irani holds a BS degree and an MBA degree from the University of California, Irvine The Paul Merage School of Biness.- Zackary Irani，他担任公司的董事。1997年4月29日以来，他担任公司的董事长和首席执行官。此前，他担任公司的业务发展副总裁。1986年以来，他一直担任公司的职务。在2008年和2009年的财政期间，他也担任Lancer Orthodontics, Inc.的董事长。从1997年4月到2004年4月，他担任Lancer的首席执行官。
- Zackary Irani has served as a Director, Chief Executive Officer of the Company since April 1997. Until June 2024, Mr. Zackary Irani served as the Chairperson of the Board from April 1997. Prior to that time, Mr. Zackary Irani served as the Company's Vice President of Biness Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Zackary Irani also served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and Mexico, and served as Lancer's Chief Executive Officer from April 1997 until April 2004. Mr. Zackary Irani holds a BS degree and an MBA degree from the University of California, Irvine The Paul Merage School of Biness.
- Gary Lu
Gary Lu，自2023年3月起担任公司首席财务官。卢先生在SEC上市公司和私有公司的公司战略、财务管理、运营、筹资和并购活动方面拥有20多年的丰富经验。在加入本公司之前，从2019年9月至2023年2月，卢先生曾在领先的无担保贷款平台Happy Money担任财务总监兼财务副总裁。2019年1月至2019年9月，卢先生在软件公司Verb Technology Company, Inc.（纳斯达克股票代码：VERB）担任财务总监和副总裁。2015年1月至2019年1月，卢先生在FirstService Residential Management，Inc.担任西南公司副总裁，该公司是一家物业管理公司，也是FirstService Corporation（纳斯达克股票代码：FSV）最大的子公司。2014年10月至2015年1月，他在全国排名靠前的骨科护理机构Hoag Orthopedic Institute，LLC担任公司财务总监和财务主管。2008年12月至2014年10月，他在半导体制造公司Broadcom Inc.（纳斯达克股票代码：AVGO）担任多个金融交叉部门的职务。卢先生的职业生涯始于专业服务公司安永律师事务所，2003年9月至2008年11月担任鉴证经理，为该公司的上市公司和私营公司客户提供鉴证服务。卢先生是一名注册会计师，在加州大学洛杉矶分校（UCLA）获得经济学和会计学学士学位。
Gary Lu has served as the Chief Financial Officer of the Company since March 2023. Mr. Gary Lu hass over 20 years of diverse extensive experience with SEC publicly traded and privately held companies in corporate strategy, financial management, operations, fundraising, and merger and acquisition activities. Prior to joining the Company, from September 2019 to February 2023, Mr. Gary Lu served as the Controller and Vice President of Finance at Happy Money, a leading platform for unsecured lending. From January 2019 to September 2019, Mr. Gary Lu served as Controller and Vice President of Finance at Verb Technology Company, Inc. (NASDAQ: VERB), a software company. From January 2015 to January 2019, Mr. Gary Lu served as Vice President Southst Corporate Controller at FirstService Residential Management, Inc., a property management company, and the largest subsidiary of FirstService Corporation (NASDAQ: FSV). From October 2014 to January 2015, he served as the Corporate Controller and Head of Finance at Hoag Orthopedic Institute, LLC, a nationally ranked organization for orthopedic care. From December 2008 to October 2014, he served within vario finance cross disciplined roles at Broadcom Inc. (NASDAQ: AVGO), a semi conductor manufacturing company. Mr. Gary Lu began his career at Ernst & Young, LLP, a professional services company, where he served as an Assurance Manager from September 2003 to November 2008, and provided assurance services to both publicly traded and private company clients of the firm. Mr. Gary Lu is a certified public accountant and received a BA in Economics and Accounting from the University of California, Los Angeles (UCLA).- Gary Lu，自2023年3月起担任公司首席财务官。卢先生在SEC上市公司和私有公司的公司战略、财务管理、运营、筹资和并购活动方面拥有20多年的丰富经验。在加入本公司之前，从2019年9月至2023年2月，卢先生曾在领先的无担保贷款平台Happy Money担任财务总监兼财务副总裁。2019年1月至2019年9月，卢先生在软件公司Verb Technology Company, Inc.（纳斯达克股票代码：VERB）担任财务总监和副总裁。2015年1月至2019年1月，卢先生在FirstService Residential Management，Inc.担任西南公司副总裁，该公司是一家物业管理公司，也是FirstService Corporation（纳斯达克股票代码：FSV）最大的子公司。2014年10月至2015年1月，他在全国排名靠前的骨科护理机构Hoag Orthopedic Institute，LLC担任公司财务总监和财务主管。2008年12月至2014年10月，他在半导体制造公司Broadcom Inc.（纳斯达克股票代码：AVGO）担任多个金融交叉部门的职务。卢先生的职业生涯始于专业服务公司安永律师事务所，2003年9月至2008年11月担任鉴证经理，为该公司的上市公司和私营公司客户提供鉴证服务。卢先生是一名注册会计师，在加州大学洛杉矶分校（UCLA）获得经济学和会计学学士学位。
- Gary Lu has served as the Chief Financial Officer of the Company since March 2023. Mr. Gary Lu hass over 20 years of diverse extensive experience with SEC publicly traded and privately held companies in corporate strategy, financial management, operations, fundraising, and merger and acquisition activities. Prior to joining the Company, from September 2019 to February 2023, Mr. Gary Lu served as the Controller and Vice President of Finance at Happy Money, a leading platform for unsecured lending. From January 2019 to September 2019, Mr. Gary Lu served as Controller and Vice President of Finance at Verb Technology Company, Inc. (NASDAQ: VERB), a software company. From January 2015 to January 2019, Mr. Gary Lu served as Vice President Southst Corporate Controller at FirstService Residential Management, Inc., a property management company, and the largest subsidiary of FirstService Corporation (NASDAQ: FSV). From October 2014 to January 2015, he served as the Corporate Controller and Head of Finance at Hoag Orthopedic Institute, LLC, a nationally ranked organization for orthopedic care. From December 2008 to October 2014, he served within vario finance cross disciplined roles at Broadcom Inc. (NASDAQ: AVGO), a semi conductor manufacturing company. Mr. Gary Lu began his career at Ernst & Young, LLP, a professional services company, where he served as an Assurance Manager from September 2003 to November 2008, and provided assurance services to both publicly traded and private company clients of the firm. Mr. Gary Lu is a certified public accountant and received a BA in Economics and Accounting from the University of California, Los Angeles (UCLA).